Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26161632 | 0.97 | HRH3 (0.43) | HRH3TSHR | |
| SCHEMBL7182245 | 0.94 | HRH3 (0.47) | HRH3TSHR | |
| SCHEMBL14586412 | 0.92 | HRH3 (0.46) | HRH3 | |
| SCHEMBL25884127 | 0.91 | HRH3 (0.46) | HRH3TSHR | |
| SCHEMBL25960823 | 0.91 | HRH3 (0.46) | HRH3TSHR | |
| SCHEMBL25939787 | 0.89 | HRH3 (0.44) | HRH3 | |
| SCHEMBL133695 | 0.87 | HRH3 (0.41) | HRH3TSHR | |
| SCHEMBL8462300 | 0.85 | HRH3 (0.48) | HRH3TSHR | |
| SCHEMBL14586099 | 0.85 | HRH3 (0.40) | HRH3 | |
| SCHEMBL19164021 | 0.84 | HRH3 (0.39) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218523-A1 | CORROSION RESISTANT COATING SYSTEMS | THE BOEING COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20230383148-A1 | NONAQUEOUS SOL-GEL FOR ADHESION ENHANCEMENT OF WATER-SENSITIVE MATERIALS | THE BOEING COMPANY | 2023-11-30 | — | — | US | disclosed |
| US-20230357595-A1 | CORROSION RESISTANT ADHESIVE SOL-GEL | THE BOEING COMPANY | 2023-11-09 | — | — | US | disclosed |
| US-20230357592-A1 | CORROSION RESISTANT ADHESIVE SOL-GEL | THE BOEING COMPANY | 2023-11-09 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20140155605-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-06-05 | — | — | US | disclosed |
| US-8680253-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-03-25 | — | — | US | disclosed |
| US-8450268-B2 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2013-05-28 | — | — | US | disclosed |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2012-02-16 | — | — | US | disclosed |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2011-07-21 | — | — | US | disclosed |
| US-7741281-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. | 2009-07-02 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | HRH3 717/4885TSHR 1242/4885 |
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | MTTP, CETP, LNPEP | HRH3 2107/4885TSHR 1569/4885 |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | TERT, VIP, YWHAZ | HRH3 4436/4885TSHR 691/4885 |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GHRHR, GIPR | HRH3 444/4885TSHR 58/4885 |
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | PRDX5, ANXA5, PRDX1 | HRH3 2616/4885TSHR 3527/4885 |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | HRH3 1124/4885TSHR 2689/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | HRH3 4130/4885TSHR 1595/4885 |
| US-20140155605-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | HRH3 2792/4885TSHR 1795/4885 |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | HRH3 2723/4885TSHR 3845/4885 |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | HRH3 2792/4885TSHR 1795/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | HRH3 4378/4885TSHR 1050/4885 |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | HRH3 2792/4885TSHR 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.